Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Regeneron Pharmaceuticals
Related studies linked through entity extraction aliases.
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)
- Status
- COMPLETED
- Phase
- PHASE1
Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
- Status
- WITHDRAWN
- Phase
- PHASE4
Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
- Status
- COMPLETED
- Phase
- PHASE3
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
- Status
- TERMINATED
- Phase
- PHASE3
Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
- Status
- COMPLETED
- Phase
- PHASE4
Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)
- Status
- COMPLETED
- Phase
- PHASE1
Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)
- Status
- COMPLETED
- Phase
- PHASE1
Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects
- Status
- COMPLETED
- Phase
- PHASE1
CLinical Prediction Rule Score in Veterans
- Status
- WITHDRAWN
- Phase
- N/A
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
- Status
- COMPLETED
- Phase
- PHASE1
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
- Status
- COMPLETED
- Phase
- PHASE3
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
- Status
- COMPLETED
- Phase
- PHASE3
Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
- Status
- COMPLETED
- Phase
- PHASE2